relatlimab,nivolumab
bms
['nivo', 'neopredict', 'nivolumab', 'relatlimab', 'lung']
results from the phase 2 neopredict trial showed that the primary end point of feasibility of treatment in patients with surgical resection of non small cell lung cancer was reached in those given preoperative nivolumab plus relatlimab. #esmo22 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.